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Background: Activated hepatic stellate cells (aHSCs) play an important role in the progression of hepatocellular
carcinoma (HCC). Here, we determined if cytokines secreted in response to the herbal compound “Songyou Yin”
(SYY) treatment of aHSCs could influence invasiveness and metastatic capabilities of hepatoma cells.
Methods: Primary rat hepatic stellate cells (HSCs) were isolated, activated, divided into SYY treated and untreated
(nSYY) groups, and conditioned media (CM-SYY and CM-nSYY, respectively) were collected. The hepatoma cell line,
McA-RH7777 was cultured for 4 weeks with SYY, CM-SYY, and CM-nSYY, designated McA-SYY, McA-SYYCM and
McA-nSYYCM. The invasiveness and metastatic capabilities were evaluated using Matrigel invasion assay in vitro and
pulmonary metastasis in vivo. Matrix metalloproteinase-2 (MMP-2), MMP-9, E-cadherin, N-cadherin, and vimentin
protein levels in McA-SYYCM and McA-nSYYCM were evaluated by Western blot. Cytokine levels in conditioned
media were tested using enzyme-linked immunosorbent assay (ELISA).
Results: Matrigel invasion assay indicated that the number of McA-SYYCM cells passing through the basement
membrane was less than in McA-nSYYCM cells (P < 0.01). Similar results were also observed in vivo for lung
metastasis. McA-SYYCM cells showed less pulmonary metastasis capabilities than McA-nSYYCM cells (P < 0.001). The
reduced expression of MMP-2 and reversed epithelial to mesenchymal transition with E-cadherin upregulation, and
N-cadherin and vimentin downregulation were also found in McA-SYYCM compared to McA-nSYYCM. Metastasis-
promoting cytokines hepatocyte growth factor, interleukin-6, transforming growth factor-β1, and vascular
endothelial growth factor were markedly decreased in CM-SYY compared to CM-nSYY.
Conclusions: SYY attenuates hepatoma cell invasiveness and metastasis capabilities through downregulating
cytokines secreted by activated hepatic stellate cells.
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Liver cancer (mainly hepatocellular carcinoma, HCC) in
men is the fifth most frequently diagnosed cancer world-
wide, but the second most frequent cause of cancer
death [1]. The majority of HCC patients have a back-
ground of chronic liver disease that primarily develops
in cirrhosis, such as chronic infection by hepatitis B
virus and hepatitis C virus, alcoholic injury [2]. More-
over, HCC may complicate non-alcoholic fatty liver dis-
ease (NAFLD) with mild or absent fibrosis, greatly
expanding the population of HCC patients potentially at
higher risk [3]. Activated hepatic stellate cells (aHSCs)
have a key role in fibrogenesis and in filtrates of the
HCC stroma, where they could play a critical role in
HCC progression. Therefore, aHSCs are recognized as
central in the development and progression of he-
patocellular carcinoma [4,5]. Unfortunately, only limi-
ted therapeutic options are currently available for this
condition.
Oriental herbal medicines have been used to treat ma-
lignancies since ancient times [6]. Experimental studies
showed that extracts from herbal medicines had antican-
cer potential [7-13]. Bu-Zhong-Yi-Qi Tang, a mixture of
ten herbs was found to suppress the growth of hepatoma
cells [14]. Sho-Saiko-To, a compound of seven herbs was
reported to inhibit proliferation of KIM-1 human he-
patoma cells [15]. Recent studies revealed that the anti-
cancer activity of herbal medicines was linked to
modulation of apoptotic signaling, the cell cycle, angio-
genic factors, invasion, and metastatic events in cancer
cells [16-19]. We have recently reported that Songyou
Yin (SYY), a mixture of five herbs inhibited HCC
growth, prolonged survival by inducing tumor apoptosis
associated with caspase-3 activation, and inhibited in-
vasiveness associated with downregulation of matrix
metalloproteinase-2 (MMP-2) [20]. Xiong et al. [21]
found that increased HCC metastatic potential after
oxaliplatin treatment could be attenuated by SYY. Al-
though the tumor suppressive effects of SYY on HCC
have been confirmed, the relationship between SYY and
aHSCs, which are the most important mesenchymal cells
in the tumor microenvironment, has not yet been
established.
Hepatic stellate cells (HSCs) are activated in response
to liver damage, and can transdifferentiate into myo-
fibroblasts (MFs), leading to the development of hepatic
fibrosis [22,23]. Recent literature has highlighted the
cross-talk between tumor cells and aHSCs in the patho-
genesis of HCC. Wang et al. [24] demonstrated that can-
cer associated fibroblasts (CAFs) obtained from lung
cancer tissue produced hepatocyte growth factor (HGF)
which activated the c-Met pathway, leading to invasion
and metastasis in cancer cells. Studebaker et al. [25]
reported that fibroblasts isolated from breast cancercould enhance cancer cell invasiveness in an interleukin-
6 (IL-6) dependent manner. Mazzocca et al. [26] found
that transforming growth factor-β (TGF-β) receptor in-
hibitor LY2109761 could inhibit production of TGF-β
secreted by CAFs, and block the cross-talk between
CAFs and HCC, and thus inhibit the progression of
HCC. Therefore, prevention of aHSCs in the tumor
microenvironment may be a potential strategy to prevent
and treat HCC.
In the present study, we determined if SYY could affect
growth factors secreted by aHSCs, block the cross-talk
between aHSCs and HCC, and indirectly influence the
invasiveness and metastatic potential of hepatoma cells.
Methods
Characterization and preparation of herbal extracts
The Chinese herbal medicine formula SYY is a dietary
component authorized by the Chinese State Food and
Drug Administration (Grant No. G20070160), which
includes five Chinese medicinal herbal extracts with fin-
gerprint in the following proportions (w/w): Salvia
miltiorrhiza Bge., 14.3%; Astragalus membranaceus Bge.,
14.3%; Lycium barbarum L., 23.8%; Crataegus pinnatifida
Bge., 23.8% and Trionyx sinensis Wiegmann, 23.8% (all
from China) [20]. SYY used in vitro with the same batch
number (#20110401) was produced by Shanghai Fang Xin
Pharmaceutical Technology Co., Ltd. (Shanghai, China).
The 800 mg/ml SYY preparation was sterilized with two
0.22 μm filtrations (Millipore, Billerica, MA, USA) and
prepared for further use in vitro.
Animals
Twelve-week-old inbred male Buffalo rats (300 g ± 20 g)
used in this study were obtained from the Chinese Acad-
emy of Science and maintained under pathogen free
conditions. The experimental protocol was approved
by the Shanghai Medical Experimental Animal Care
Commission.
Isolation and preparation of rat liver HSCs
Rat liver HSCs were isolated by collagenase digestion and
purified by density gradient centrifugation using Percoll
(Sigma-Aldrich, St. Louis, MO, USA), as previously de-
scribed [27] with slight modifications. The liver was per-
fused through the portal vein with buffer I [D-Hanks
(Invitrogen, Grand Island, NY, USA) media containing
0.05% collagenase IV (Sigma-Aldrich), 0.1% pronase E
(Roche, Madison, WI, USA)] at 37°C for 20 min. The liver
was then excised and cut into small pieces in collagenase
buffer containing 0.05% collagenase IV, 0.02% pronase E,
0.01% DNase (Sigma-Aldrich) for an additional 30 min.
The suspension was filtered through nylon gauze and the
filtrate was sedimented twice by centrifugation at 70 × g
for 5 min at 4°C to remove parenchymal cells. The HSCs
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fer and collected by centrifugation at 650 × g for 5 min at
4°C. Cells were resuspended in DMEM (Invitrogen) and
purified by flotation on a density cushion of Percoll (30%)
by centrifugation at 1800 × g for 20 min at 4°C. The HSCs
fraction was collected, sedimented at 650 × g for 7 min,
and then resuspended in DMEM containing 10% fetal bo-
vine serum (FBS).
Preparation of conditioned media (CM)
Freshly isolated HSCs were cultured in high glucose
DMEM containing 10% (v/v) FBS. Two weeks later,
HSCs were activated and transferred into T75 flasks
(1 × 106 cells). The next day, the cultures were removed
and 12 ml fresh serum free DMEM medium was added
to the SYY sample (containing 2 mg/ml SYY) and con-
trol sample (no SYY). Twenty-four hours later, the cul-
tures were centrifuged at 1000 × g and the supernatants
were collected and designated CM-SYY (with SYY) and
CM-nSYY (no SYY). All culture reagents were pur-
chased from Invitrogen.
Lactate dehydrogenase (LDH) cytotoxicity assay
The cytotoxicity detection kit PLUS (Roche) is a precise
and fast colorimetric assay for quantitating cytotoxicity
by measuring lactic dehydrogenase (LDH) activity re-
leased from damaged cells. The aHSCs were cultured
and digested when the density reached 80%. After tryp-
sin digestion, the cells were counted and pipetted into
96-well plates at 1000 cells/well. On the same plate,
background controls (medium only); low controls (spon-
taneous LDH release), high controls (maximum LDH re-
lease), and experimental samples (2 mg/ml SYY) were
prepared according to the manufacturer’s instructions.
The 96-well plates were incubated in a humidified incu-
bator at 37°C in 5% CO2 for 4 h, 8 h, and 12 h. Results
were expressed as the mean absorbance of wells in
groups at 492 nm. Cytotoxicity (%) was calculated using
the equation: (experimental value − low control) / (high
control − low control) × 100%.
Immunofluorescence and western blot assays
The expression of α-smooth muscle actin (α-SMA)
(Abcam, Cambridge, MA, USA) and desmin (Epitomics,
Burlingame, CA, USA) were determined by immunofluor-
escence as previously described [28]. The aHSCs were
grown on glass cover slips to 20 − 30% confluency, and
then fixed, permeabilized, blocked, and incubated with
α-SMA or desmin overnight at 4°C. Slides were then
washed and incubated with FITC-conjugated secondary
antibody (Jackson Labs, Bar Harbor, ME, USA). Cells
were counterstained with 4'-6-diamidino-2-phenylindole
(DAPI) to visualize cell nuclei and detected by fluores-
cence microscopy (Olympus, Tokyo, Japan). The proteinexpression of MMP-2, MMP-9, E-cadherin, N-cadherin,
vimentin, and actin in McA-SYYCM and McA-nSYYCM
conditioned media were detected by western blot assays as
previously described with slight modifications [28]. And
the primary antibodies were diluted according to the man-
ufacturer’s instructions (Epitomics). The concentration of
protein extracted from the McA-SYYCM and McA-
nSYYCM were determined by the BCA Protein Assay Kit
(Beyotime, Shanghai, China).
Cells and cell cultures
The hepatoma cell line McA-RH7777 originally derived
from the Buffalo rat was obtained from the American
Type Culture Collection (Manassas, VA, USA). To deter-
mine the effect of conditioned media (CM) from SYY
treated and untreated aHSCs, McA-RH7777 cells were
cultured and passaged (every 4–5 days) in CM-nSYY
(added with 10% FBS) and CM-SYY (added with 10%
FBS and 2 mg/ml SYY) for 4 weeks and designated
McA-SYYCM and McA-nSYYCM. McA-RH7777 cells
cultured and passaged (every 4–5 days) in DMEM
containing 10% FBS and 2 mg/ml SYY for 4 weeks were
named McA-SYY (no CM added).
Cell invasion assays
Cell invasion was assessed by transwell assays as described
previously [29] (Boyden chambers, Corning, Flintshire,
UK) using McA-SYY, McA-SYYCM, and McA-nSYYCM
conditioned media. Eighty μl of Matrigel (1:8 dilution with
DMEM) (BD Biosciences, San Jose, CA, USA) was added
to each well 4 h before cells were seeded onto the mem-
brane. Then, 5 × 104 cells in serum free DMEM were
seeded into the upper chamber of each well on the mem-
brane (8.0 μm pore size) of a 24-well plate. DMEM
containing 10% FBS was added to the lower chamber of
each well. After 48 h, cells reaching the underside of the
membrane were stained with Giemsa (Sigma-Aldrich) and
counted at × 200 magnification.
Enzyme-linked immunosorbent assay
Cytokines secreted into the media of CM-SYY and
CM-nSYY were quantified by ELISA kits (R&D Labs,
Minneapolis, MN, USA). Cytokines measured included
HGF, IL-2, IL-6, IL-10, IL-12, matrix metalloproteinase-
2 (MMP-2), MMP-9, transforming growth factor-β
(TGF-β), tumor necrosis factor-α (TNF-α), and vascular
endothelial growth factor (VEGF). Assays were per-
formed according to the manufacturer’s instructions and
conducted in quadruplicate which were described previ-
ously [30].
In vivo evaluation of tumor metastasis
Four weeks after co-cultivation, McA-SYY, McA-SYYCM,
and McA-nSYYCM cells were harvested, washed, and
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(0.1 ml cell suspension) were injected into the left lobe
livers of 6-week-old Buffalo rats. Each group contained 6
rats. Four weeks later, animals were sacrificed and the
numbers of lung metastatic nodules were evaluated by mi-
croscopy of serial sections of the right lung tissue block
which is on behalf the entire pulmonary metastasis. And
this method was reported by our group in previous
research [31].
Statistical analysis
Differences in the quantitative data obtained from cy-
tokine expression levels, invasiveness, and pulmonary
metastatic nodules among the three groups of hepatoma
cells were evaluated by t-test. Statistical analysis was
performed with SPSS 15.0 software for Windows (SPSS
Inc. Chicago, IL, USA). P < 0.05 was considered as statis-
tically significant.
Results
Isolation, activation, and identification of HSCs
The results are presented in Figures 1A-1C. Hepatic stel-
late cells (HSCs) were isolated from Buffalo rat liverFigure 1 Freshly isolated HSCs from buffalo rats were quiescent, rich
Fourteen days after isolation, HSCs were activated and developed into fibro
(B), and α-SMA (C) followed by FITC-conjugated secondary antibody, and nmesenchymal cells which were quiescent, rich in lipid
droplets, and had spontaneous green fluorescence on
the first day after isolation. Fourteen days later, HSCs
developed into fibroblast-like cells (Figure 1A). The pur-
ity of aHSCs was approximately 95% as determined by
desmin immunostaining, which only stains quiescent
and activated HSCs (Figure 1B). The isolated HSCs were
100% activated with strong alpha smooth muscle actin
(α-SMA) expression throughout the cells (Figure 1C).SYY exhibited no significant cytotoxicity in aHSC and HCC
cell lines
The results are presented in Figure 2C. Activated Hepatic
stellate cells (aHSCs) and the hepatoma cell line McA-
RH7777 were treated with SYY 2 mg/ml for 0, 4, 8, 12 h
demonstrated strange decline in release of lactate de-
hydrogenase (LDH) compared with the control group.
When LDH release of the control group was set at 0%, the
relative emission of LDH at 4, 8, 12 h was −7.07 ± 3.39%, -
5.20 ± 2.17%, -5.76 ± 1.92% in aHSCs and −4.76 ± 1.32%, -
6.04 ± 2.37%, -6.44 ± 1.97% in McA-RH7777. There was
no statistically significant difference between the control
and experimental groups (Figure 2C), indicating that SYY
did not exhibit acute cytotoxicity.in lipid droplets and with spontaneous green fluorescence.
blast-like cells (A). Activated HSCs were immunostained with desmin
uclei were stained with DAPI.
Figure 2 The number of pulmonary nodules implanted with McA-SYYCM cells was less than the nodule number from McA-nSYYCM
cells. McA-SYY cell implants had the smallest number of nodules (A, B). The aHSCs and McA-RH7777 cells, which were treated with 2 mg/ml SYY
for 4 h, 8 h, and 12 h, demonstrated no increased release of LDH, indicating no acute cytotoxicity (C).
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SYY treated aHSCs showed reduced invasiveness
The results are presented in Figure 3A-3C. The cell
invasion assay demonstrated that the number of McA-
SYYCM cells passing through the basement membrane
was less than the McA-nSYYCM cells (33.83 ± 3.87 vs.
17.50 ± 2.43, P < 0.01). There was only a small number of
McA-SYY cells passing through the basement mem-
brane, which was the lowest number of the three cell
samples (12.33 ± 2.16, P < 0.05) (Figure 3A, 3B). Epithe-
lial to mesenchymal transition (EMT) is characterized by
the loss of the epithelial marker E-cadherin, and expres-
sion of mesenchymal markers such as N-cadherin and
vimentin which is regarded as a critical characteristic
of tumor invasion and metastasis. In the present study,
E-cadherin upregulation with N-cadherin and vimentin
downregulation were found in McA-SYYCM cells com-
pared to McA-nSYYCM cells. MMP-2, as a predictor of
recurrence and metastasis in cancer, was also found down-
regulated in McA-SYYCM cells. Expression of MMP-9 was
low, with no significant differences in expression found in
both McA-SYYCM and McA-nSYYCM cells (Figure 3C).Hepatoma cells treated by CM from SYY treated aHSCs
showed reduced pulmonary metastasis
The results are presented in Figure 2A-2B. To investi-
gate whether CM from SYY treated aHSCs could attenu-
ate hepatoma cell pulmonary metastatic potential, three
groups of cells (McA-SYY, McA-SYYCM, and McA-
nSYYCM) were implanted into rat livers. Four weeks
later, rats were sacrificed and the nodules of pulmonary
metastasis were evaluated. The number of pulmonary
nodules implanted with McA-SYYCM cells was reduced
when compared to McA-nSYYCM cells (6.00 ± 2.00 vs.
14.67 ± 3.51, P < 0.001). In McA-SYY group there was
only a small number of pulmonary nodules, which
showed the lowest number of the three groups (2.83 ±
2.56, P < 0.05) (Figure 2A, 2B).
SYY treatment altered the cytokines secretion of aHSCs
The results are presented in Table 1. Cytokines in CM
collected from aHSCs could significantly induce prolifera-
tion and migration of hepatoma cells. Cytokines in CM
from SYY treated aHSCs, which attenuate hepatoma cell
Figure 3 The transwell assays demonstrated that McA-SYYCM cells passed through the basement membrane in less number than
McA-nSYYCM cells, and McA-SYY cells were the lowest in number (A). The number of invading cells is expressed as mean ± SD (B). Based
upon western blots, E-cadherin was upregulated, while N-cadherin, vimentin, and MMP-2 were downregulated in McA-SYYCM cells compared to
McA-nSYYCM cells. MMP-9 levels were low in both McA-SYYCM and McA-nSYYCM cells, and were not statistically different (C).
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the conditioned media, HGF (144.62 ± 7.12 pg/ml vs.
115.49 ± 10.17 pg/ml, P = 0.0034), IL-6 (17.56 ± 0.33 pg/ml
vs. 13.76 ± 1.41 pg/ml, P = 0.0215), TGF-β (20.42 ±
1.49 pg/ml vs. 17.69 ± 0.82 pg/ml, P = 0.0086), and VEGF
(132.34 ± 8.27 pg/ml vs. 122.74 ± 10.62 ng/ml, P = 0.0481)
were markedly decreased in CM-SYY compared to CM-
nSYY (Table 1).Table 1 Cytokine expression in CM-nSYY and CM-SYY
using ELISA Assay
CM-nSYY mean ± SD CM-SYY mean ± SD P value
HGF* 144.62 ± 7.12 115.49 ± 10.17 0.0034
IL-2* 14.28 ± 1.02 14.37 ± 0.42 0.860
IL-6* 17.56 ± 0.33 13.76 ± 1.41 0.0215
IL-10* 16.45 ± 1.88 17.56 ± 2.65 0.521
IL-12* 13.72 ± 0.69 13.50 ± 3.35 0.903
MMP-2** 23.10 ± 2.17 22.33 ± 1.63 0.590
TGF-β* 20.42 ± 1.49 17.69 ± 0.82 0.0086
TNF-a* 23.84 ± 3.24 23.01 ± 2.95 0.716
VEGF* 132.34 ± 8.27 122.74 ± 10.62 0.0481
* pg/ml.
**ng/ml.
Data were obtained from 4 tests. Paired t-test was used for statistical analyses.Discussion
Liver fibrosis is strongly associated with HCC, with 90%
of HCC cases arising in cirrhotic livers [32]. HSCs as
one of the key cell types responsible for liver fibrosis
were once known as lipocytes, Ito cells, or perisinusoidal
cells. HSCs are activated in response to liver damage
and transdifferentiate into MFs which lead to the de-
velopment of hepatic fibrosis. They also infiltrate the
stroma of liver tumors as CAFs promoting HCC cell
proliferation and metastasis. Multiple mechanisms may
be involved in the aHSCs which induce changes of the
hepatic tumor phenotype. It is reported that aHSCs
could interact with hepatoma cells via secretion of cyto-
kines, extracellular matrix-mediated interactions, and
direct cell-to-cell contacts [33]. In the present study, we
found that SYY could indirectly attenuate hepatoma cell
invasiveness and pulmonary metastasis through downre-
gulation of cytokines secreted by aHSCs.
The development of distant metastasis requires the in-
vasion of cancer cells from the primary tumor into the
surrounding tissue. To acquire such invasive abilities,
epithelial cancer cells must undergo several phenotypic
changes, and aHSCs as one of the most important mem-
bers in the tumor environment play a critical role in
modulating the phenotypic changes. Amann et al. [34]
demonstrated that CM collected from aHSCs could
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are many cytokines secreted by aHSCs that are associ-
ated with tumor invasion and metastasis, ingcluding
HGF, EGF, IL-1, IL-2, IL-6, MMP-2, MMP-9, TGF-β,
TNF-α, VEGF and Wnt families [35-37]. Inhibition of
TGF-β receptor activity interrupted the cross-talk be-
tween HCC cells and CAFs and therefore prevented
tumor growth, intravasation and metastasis via inhibiting
the proliferation of CAFs [26]. Studebaker et al. [25]
found soluble IL-6 produced by issue-specific fibroblasts
could promote growth and invasion of breast cancer
cells which can be inhibited by the removal or inhibition
of IL-6. Li et al. [38] found Wnt2 secreted by tumour fi-
broblasts promoted tumour progression in oesophageal
cancer by activation of the Wnt/b-catenin signalling
pathway. It was also reported that HGF upregulation
promoted carcinogenesis and epithelial-mesenchymal
transition in hepatocellular carcinoma via Akt and COX-
2 pathways [39]. In the present study, we quantified ten
cytokines secreted into the media of CM-SYY and CM-
nSYY and found that HGF, IL-6, TGF-β, and VEGF were
downregulated in CM from SYY treated aHSCs.
In the further study, we determined if CM from SYY
treated aHSCs could block the cross-talk between
aHSCs and HCC, and indirectly influence the invasive-
ness and metastatic potential of hepatoma cells. We cul-
tured Buffalo rat hepatoma cells (McA-RH7777) in CM-
SYY for four weeks and found reduced invasiveness and
pulmonary metastasis capability compared to McA-
nSYYCM cells (no SYY). EMT, which is regarded as a
critical characteristic of tumor invasion and metastasis is
characterized by the loss of epithelial marker E-cadherin
and increased expression of mesenchymal markers such
as N-cadherin and vimentin [40]. We found that EMT
was reversed with the upregulation of E-cadherin and
downregulation of N-cadherin and vimentin in McA-
SYYCM compared to McA-nSYYCM cells. MMP-2
which is a predictor of recurrence and metastasis risk in
cancer was also found downregulated in McA-SYYCM
cells.
SYY is a Chinese herbal medicine formula consisting of
five herbs. Some components of SYY such as tanshinone
and astragalus saponins have demonstrated efficacy in
treatment of malignancies [41,42]. We have shown that
SYY could effectively inhibit tumor growth and metastasis,
reverse the molecular changes consistent with EMT, and
increase survival in a HCC nude mouse model [20,21]. In
the present study, we found that SYY could attenuate
hepatoma cell invasiveness and metastasis through
downregulating cancer-promoting cytokines secreted by
aHSCs. Recently, fibrosis-dependent tumorigenic mecha-
nisms have been reported by many researchers [43,44].
However, studies which support anti-fibrotic therapeutic
strategies to prevent and treat HCC are few. Treatment ofthe underlying cause of chronic liver injury and liver
transplantation are the only two currently available thera-
peutic interventions capable of modifying liver fibrosis
[45]. Elimination of the causative agent is often not pos-
sible, and liver transplantation has many drawbacks, in-
cluding shortage of donors, costs, procedure-associated
risks, and complications of immunosuppressive drugs.
Our research suggests that traditional Chinese medicines,
such as SYY may provide potential candidates to reduce
liver cirrhosis and prevent liver tumors.
We have shown that SYY could attenuate hepatoma cell
invasiveness and metastasis through downregulation of cy-
tokines secreted by activated hepatic stellate cells. How-
ever, several fundamental questions remain to be answered
concerning the ability of SYY to reverse liver fibrosis.
Therefore, mouse models with a cirrhosis background
should be established and the relationship among HCC,
aHSCs, and SYY must be evaluated in future studies. Fu-
ture studies will also determine if SYY can be useful in
clinically treating human tumors.
Conclusions
SYY attenuates hepatoma cell invasiveness and metastasis
capabilities through downregulating cytokines secreted by
activated hepatic stellate cells.
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